On November 20, 2026, Guangzhou Burning Rock Dx Co., Ltd. (NASDAQ: BNR, Burning Rock) and Beijing Avistone Biotechnology Co., Ltd. (Avistone) jointly announced that the companion diagnostic kit for Andamertinib Benzoate Capsules (安比锐®, Andamertinib), developed through their collaboration, has received approval from China’s National Medical Products Administration (NMPA). The kit is approved for detecting EGFR exon 20 insertion (exon20ins) mutations in patients with non-small cell lung cancer (NSCLC), supporting the identification of eligible patients and informed treatment decisions.
Andamertinib, an EGFR exon 20 insertion (exon20ins) inhibitor independently developed by Avistone Pharmaceutical (Ningbo) Co., Ltd. (Ningbo Avistone), a wholly owned subsidiary of Avistone, received conditional approval from the NMPA on April 30, 2026. It is indicated for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an exon 20 insertion mutation in EGFR.
On November 14, 2026, Andamertinib was included for the first time in China’s 2026 National Reimbursement Drug List (NRDL), which will take effect on January 1, 2027, potentially improving access to and affordability of this innovative treatment.



